Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorSinan, Umit Yasar
dc.contributor.authorDemir, Rengin
dc.contributor.authorCanbolat, Ismail Polat
dc.contributor.authorPalabiyik, Mert
dc.contributor.authorKaya, Aysem
dc.contributor.authorKucukoglu, Mehmet Serdar
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T15:55:46Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T15:55:46Z
dc.date.issued2018
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.urihttps://dx.doi.org/10.14744/AnatolJCardiol.2018.60252
dc.identifier.urihttp://hdl.handle.net/11446/2126
dc.descriptionWOS: 000446230300010en_US
dc.descriptionPubMed ID: 29952361en_US
dc.description.abstractObjective: Pulmonary artery hypertension (PAH) is characterized by remodeling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance and right ventricular failure. In this study, we aimed to share our 10 years of experience dealing with pulmonary hypertension (PH) and provide information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a tertiary center. Methods: In this retrospective, single-center, observational study, we screened the patients who applied to PH outpatient clinic of Istanbul University Institute of Cardiology due to the suspicion of PAH between 2008 and 2017. While group 1, 4, and 5 PH patients were included, group 2 and 3 PH patients were excluded from the study. Results: Our study group comprised 162 patients (115 females, 71%). The female:male ratio was 2.4. The mean age was 52 +/- 16 years. Most (86.4%) of the patients were in group 1 PH (PAH). The rest (13.6%, n=22) of the patients were in group 4 PH (chronic thromboembolic PH). In group 1 PH, 45.7% of patients (n=64) were classified as having idiopathic PAH (IPAH) after excluding the alternative diagnosis using PH diagnostic algorithm. The remaining 54.3% of group 1 PH patients (n=76) had various diseases that caused PAH, which is called associated PAH (APAH); APAH group included PAH associated with congenital heart diseases (n=70), connective tissue disorders (scleroderma, n=4) and portal hypertension (n=2). Conclusion: Our data provides important information in real-life settings in terms of demographics, clinical course, PH subgroup distribution, and treatment patterns in patients with PAH in a reference tertiary center in Turkey.en_US
dc.language.isoengen_US
dc.publisherTURKISH SOC CARDIOLOGYen_US
dc.identifier.doi10.14744/AnatolJCardiol.2018.60252en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectpulmonary arterial hypertensionen_US
dc.subjectpulmonary vascular diseaseen_US
dc.subjectchronic thromboembolic pulmonary hypertensionen_US
dc.subjectdemographicsen_US
dc.subjectpulmonary arterial hypertension associated with congenital heart diseaseen_US
dc.titlePulmonary hypertension experience in an expert university hospitalen_US
dc.typearticleen_US
dc.relation.journalANATOLIAN JOURNAL OF CARDIOLOGYen_US
dc.departmentDBÜen_US
dc.identifier.issue1en_US
dc.identifier.volume20en_US
dc.identifier.startpage35en_US
dc.identifier.endpage40en_US
dc.contributor.authorID0000-0003-3137-821Xen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Sinan, Umit Yasar -- Palabiyik, Mert -- Kucukoglu, Mehmet Serdar] Istanbul Univ, Inst Cardiol, Dept Cardiol, Istanbul, Turkey -- [Demir, Rengin] Istanbul Univ, Inst Cardiol, Dept Cardiopulm Physiotherapy, Istanbul, Turkey -- [Kaya, Aysem] Istanbul Univ, Inst Cardiol, Dept Biochem, Istanbul, Turkey -- [Canbolat, Ismail Polat] Istanbul Bilim Univ, Sisli Florance Nightingale Hosp, Dept Cardiol, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster